Physician profile
Patrick J Shea
NPI 1184689705
$5,852.75
in general payments reported to CMS, 2019-2025
31 companies · $797 in 2025
The $797 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $628 · 2021: $990 · 2022: $1,178 · 2023: $751 · 2024: $843 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,481.25 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $584.07 | 2019-2023 | Xarelto |
| Amgen INC. | $513.04 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $480.13 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $403.25 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $377.49 | 2019-2025 | Farxiga |
| Atricure, INC. | $254.34 | 2022 | |
| Amarin Pharma, INC. | $254.08 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $228.46 | 2021-2025 | |
| Pfizer INC. | $226.32 | 2019-2025 | |
| Esperion Therapeutics, INC. | $179.66 | 2020-2024 | Nexletol |
| Medtronic, INC. | $128.23 | 2024 | Propel |
| Alnylam Pharmaceuticals INC. | $99.99 | 2022-2025 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $79.33 | 2020-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $76.96 | 2021-2023 | Ozempic |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $70.11 | 2019-2021 | |
| Edwards Lifesciences Corporation | $58.13 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.31 | 2020-2024 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $48.32 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $40.65 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.59 | 2019 | |
| Philips North America LLC | $27.80 | 2022 | |
| Inari Medical, INC. | $25.37 | 2022 | |
| Daiichi Sankyo INC. | $25.06 | 2024 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $19.12 | 2019 | |
| Bridgebio Pharma, INC. | $17.73 | 2025 | Attruby |
| Heartflow, INC. | $15.84 | 2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $15.10 | 2021 | |
| Lundbeck LLC | $13.54 | 2019 | |
| Chiesi USA, INC. | $12.05 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Shea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.